It is sub optimal at all levels to do a partnership. 

For the scientists in RVX, they need access to a lot more capital so they can run a Rolls Royce kind of Phase 3 trial.  5,000 patients, 500 MACE events...big kidney and dementia secondary endpoints.  It will take 2 to 3 years before the drug is finally approved by the FDA.  This is not for RVX to finish.

From our point of view, this will require RVX to raise yet more capital.  I think the availability of capital for RVX is now zero.  Just look at how hard it is to raise a few million dollars.  I just don't want RVX to keep raising ever more capital for years to come, in the event of a partnership.

DM and Norman Wong are into their 60s.  They can't be expected to hang around for too long to conduct yet more capital raises and even more trials.  Same with other top people in RVX.

Biotech companies are meant to be bought by big pharma, if they are successful.  Hardly any make it on their own for too long.  The capital requirements along with the time needed to finish trials are just too onerous...this is best done by a Pfizer kind of company.